Despite lowering its target price for bioMérieux from €111 to €104, Invest Securities reiterates its "buy" rating, believing that the in vitro diagnostics group has once again demonstrated "its resilience, with robust growth in the third quarter".

The historic levers are not weakening, and the new relays are off to a promising start", says the research firm, which continues to forecast the top end of the growth range and the middle of the EBITA range.

Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.